financetom
Business
financetom
/
Business
/
National Bank Reviews ATS Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank Reviews ATS Q4
May 16, 2024 10:48 AM

01:18 PM EDT, 05/16/2024 (MT Newswires) -- ATS Corporation's ( ATS ) consolidated revenue came in at $791.5 million (up +8% y/y; +3.5% y/y organically), +10% stronger than consensus at $721 million and NBF at $720 million.

Adjusted EPS was $0.65, again, stronger when compared to Street and NBF at $0.55.

Order backlog fell -17% y/y as bookings came in at $791 million.

National Bank analyst Maxim Sytchev notes that shares peaked in low $60's last July and are now sitting -30% below those levels. "We don't know when EV backlog growth resumes but there is the "rest" of the business that appears to move forward and with tuck-in M&A should offset transport compression in F2025E."

ATS shares are rated Outperform with $65 target price.

Price: 45.97, Change: +1.32, Percent Change: +2.96

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ryanair Q3 Revenue Surges 10% Despite Boeing Delays, Revises FY26 Traffic Growth Forecast
Ryanair Q3 Revenue Surges 10% Despite Boeing Delays, Revises FY26 Traffic Growth Forecast
Jan 27, 2025
Ryanair Holdings plc ( RYAOF ) stock is trading higher after it reported its third-quarter 2025 results. RYAAY reported revenue growth of 10% year-over-year to 2.96 billion euros ($3.158 billion, beating the $2.937 billion estimate). Quarterly earnings of $0.30 per ADS beat the analyst consensus estimate of $0.08. Scheduled revenues gained 10% YoY to 1.92 billion euros as traffic increase drove revenue increase...
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO
Jan 27, 2025
Jan 27 (Reuters) - Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based Metsera seeks to raise up to $292.2 million by offering 17.19 million shares, priced between $15 and $17 each. The weight-loss drug market, estimated to be worth...
Calavo Growers Board Selects Farha Aslam as Chair
Calavo Growers Board Selects Farha Aslam as Chair
Jan 27, 2025
09:17 AM EST, 01/27/2025 (MT Newswires) -- Calavo Growers ( CVGW ) early Monday said the directors at the produce firm have selected Farha Aslam to be it new board chair, effective immediately. Aslam succeeds Steven Hollister, who will remain on the Calavo board. Aslam is the managing partner at Crescent House Capital, an investment and strategic advisory firm she...
Israel Acquisitions, Gadfin to Merge in $200 Million Deal
Israel Acquisitions, Gadfin to Merge in $200 Million Deal
Jan 27, 2025
09:15 AM EST, 01/27/2025 (MT Newswires) -- Israel Acquisitions ( ISRL ) , a special purpose acquisition company, has agreed to merge with Gadfin, valuing the Israeli drone delivery company at $200 million, the companies said Monday. The combined company will be listed on Nasdaq and will utilize Gadfin's hydrogen-powered drones, capable of long-range, all-weather delivery of critical cargo such...
Copyright 2023-2026 - www.financetom.com All Rights Reserved